ALPHARETTA, Ga., Feb. 23, 2021 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the Company will participate in two upcoming investor conferences in March 2021:

Cowen 41st Annual Health Care Conference

Blazing New Paths in Clinical Development and Structure Panel

Tuesday, March 2, 2021 at 2:10 pm ET

33rd Annual ROTH Conference

Ophthalmology Panel

Tuesday, March 16, 2021 at 9:00 am ET

The panels will be available for attendees on the conference websites. Management will be participating in live, virtual one-on-one meetings with investors who are registered to attend the conferences.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector

^®

targets the suprachoroidal space (SCS

^®

) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations. For more information, please visit

www.clearsidebio.com

.

Investor and Media Contacts:

Jenny Kobin

Remy Bernarda


[email protected]


(678) 430-8206

Source: Clearside Biomedical, Inc.